Scheduled versus Pro Re Nata dosing in the VIEW trials

Gisbert Richard*, Jordi Monés, Sebastian Wolf, Jean François Korobelnik, Robyn Guymer, Michaella Goldstein, Christiane Norenberg, Rupert Sandbrink, Oliver Zeitz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Purpose To analyze visual acuity (VA) outcomes before and after preplanned treatment regimen change in the VIEW studies at week 52 (W52). Design Multiple post hoc analyses for retrospectively defined subgroups in 2 multicenter, multinational, double-masked trials. Participants Two thousand four hundred fifty-seven neovascular age-related macular degeneration (AMD) patients. Methods Patients were randomized to treatment with 0.5 mg ranibizumab given monthly, a 0.5-mg or 2-mg intravitreal aflibercept injection given monthly, or 2 mg intravitreal aflibercept given every other month, after 3 initial monthly doses, up to W52. From W52 through W96, patients received their original dosing assignment using a capped pro re nata (PRN) regimen, with defined retreatment criteria based on VA and morphologic signs of disease activity and mandatory dosing at least every 12 weeks. Main Outcome Measures Best-corrected VA (BCVA) and optical coherence tomography assessments were mandatory at all visits from baseline to W96. Outcomes were changes in BCVA and central retinal thickness. Outcomes were evaluated in all patients who completed 2 years of the VIEW studies using the last observation carried forward method for missing data at interim visits. Results After W52, approximately 20% of patients lost 5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or more across all treatment arms with PRN treatment. Patients who met the retreatment criterion of loss of 5 ETDRS letters or more in the first quarter of the PRN dosing phase did not recover; mean final VA loss across the 4 study arms was -4.4 to -5.8 letters. Outcomes of these patients up to W52 were indistinguishable from those of the overall population. There were no differences between groups in serious ocular adverse events or Anti-Platelet Trialists' Collaboration arterial thromboembolic events through W96. Conclusions These analyses suggest that there are subgroups of patients for whom VA outcomes in the second year of the VIEW studies were less stable than in the first year and for whom W52 seems to be an important inflection point. Although alternate reasons specific to the nature of the underlying AMD cannot be fully excluded, the switch in treatment regimen at W52 is a plausible explanation.

Original languageEnglish
Pages (from-to)2497-2503
Number of pages7
Issue number12
StatePublished - Dec 2015


FundersFunder number
Corey Eagan
Bayer HealthCare


    Dive into the research topics of 'Scheduled versus Pro Re Nata dosing in the VIEW trials'. Together they form a unique fingerprint.

    Cite this